Bclaf1 binds to SPOP, thereby inhibiting PD-L1 ubiquitination and degradation and making cancer cells sensitive to checkpoint therapy, suggesting that Bclaf1 is a novel therapeutic target for enhancing anti-tumor immunity in HCC (Yu et al., 2024). This evidence concerns the gene BCLAF1 and neoplasm.